Study on ASTX727, Venetoclax, and Gilteritinib for Treating FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Clinical Trial

Study on ASTX727, Venetoclax, and Gilteritinib for Treating FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Clinical Trial | Right2Hope